ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The US government will pay $265 million under its Operation Warp Speed program to reserve capacity for manufacturing COVID-19 vaccines at Fujifilm Diosynth Biotechnologies’ facility in College Station, Texas. The government has a similar agreement with Emergent BioSolutions in Maryland. Fujifilm says some of the capacity will be allocated to the vaccine being developed by Novavax. Fujifilm recently signed a deal to manufacture the Novavax vaccine in Morrisville, North Carolina, for clinical trials before transferring production to Texas.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X